A paradigm use of monoclonal antibodies-conjugated nanoparticles in breast cancer treatment: current status and potential approaches

dc.authoridALTAIE, Anmar/0000-0002-2183-6830
dc.authoridOZCAN BULBUL, Ece/0000-0001-7112-923X
dc.authorwosidALTAIE, Anmar/ITV-8235-2023
dc.contributor.authorAl-Taie, Anmar
dc.contributor.authorBulbul, Ece Ozcan
dc.date.accessioned2024-05-19T14:39:37Z
dc.date.available2024-05-19T14:39:37Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractMonoclonal antibodies (mAbs) are integral to cancer treatment over conventional non-specific therapy methods. This study provides a scoping review of the clinically approved mAbs, focusing on the current application of different nanocarrier technologies as drug delivery targets for mAb-conjugated nanoparticles (NPs) as potential features for breast cancer (BC) treatment. An extensive literature search was conducted between the years 2000 and 2023 using various sources of databases. The first part covered mAb classification, types, and mechanisms of action, pharmacokinetics and clinical applications in BC. The second part covered polymeric, lipid and inorganic-based NPs, which are a variety of mAb-conjugated NPs targeting BC. A total of 20 relevant studies were enrolled indicating there are three different types of nanoparticular systems (polymeric NPs, inorganic NPs and lipid-based NPs) that can be used for BC treatment by being loaded with various active substances and conjugated with these antibodies. While mAbs have altered the way in cancer treatment due to targeting cancer cells specifically, the delivery of mAbs with nanoparticulate systems is important in the treatment of BC, as NPs are still being investigated as distinctive and promising drug delivery methods that can be employed for effective treatment of BC.en_US
dc.identifier.doi10.1080/1061186X.2023.2295803
dc.identifier.endpage56en_US
dc.identifier.issn1061-186X
dc.identifier.issn1029-2330
dc.identifier.issue1en_US
dc.identifier.pmid38096045en_US
dc.identifier.scopus2-s2.0-85181211140en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage45en_US
dc.identifier.urihttps://doi.org10.1080/1061186X.2023.2295803
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4818
dc.identifier.volume32en_US
dc.identifier.wosWOS:001134479100001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Drug Targetingen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectBreast Canceren_US
dc.subjectImmunotherapyen_US
dc.subjectNanoparticlesen_US
dc.subjectMonoclonal Antibodiesen_US
dc.subjectTargeting Drug Deliveryen_US
dc.titleA paradigm use of monoclonal antibodies-conjugated nanoparticles in breast cancer treatment: current status and potential approachesen_US
dc.typeReview Articleen_US

Dosyalar